Subcutaneous administration of collagen-polyvinylpyrrolidone down regulates IL-1beta, TNF-alpha, TGF-beta1, ELAM-1 and VCAM-1 expression in scleroderma skin lesions

Abstract

In this study the effect of collagen-polyvinylpyrrolidone (collagen-PVP) vs. triamcinolone acetonide (Triam) in scleroderma (SSc) skin lesions was evaluated. Ten SSc patients were treated weekly with subcutaneous injections of 0.2 mL Triam (8 mg/mL) or 0.2 mL collagen-PVP (1.66 mg collagen). Skin biopsies were obtained from lesions before and after treatment. Tissue sections were evaluated by histology and immunohistochemistry (ELAM-1, VCAM-1, IL-1beta, TNF-alpha, TGF-beta1 and PDGF). The corticoid-treated group showed abnormal tissue architecture while the biodrug-treatment restored cutaneous appendages and type I/III collagen proportion. Cytokine and adhesion molecule expression was almost inhibited with Triam, while collagen-PVP down-regulated it. Collagen-PVP improved the tissue architecture of SSc lesions and down-regulated some proinflammatory parameters, without the side effects induced by corticoids.

Effects of Pirfenidone and Collagen-Polyvinylpyrrolidone on Macroscopic and Microscopic Changes, TGF-β1 Expression, and Collagen Deposition in an Experimental Model of Tracheal Wound Healing

“…These results corroborate the findings of several studies that topically applied Collagen-PVP and concluded that this drug enhances collagen production and organized CD in the ECM, as previously shown in the skin [1, 10, 31]. Similarly, our results corroborate the findings of other studies that reported decreased fibrosis and improved collagen organization after treating pulmonary [16, 27], tracheal [24], hepatic, and renal [28] fibrotic lesions and glaucoma [32] with PFD.…”

Ileocolonic Ulcer Treated by Endoscopic Application of Collagen-Polyvinylpyrrolidone

“…The amount of solution was chosen empirically and was injected only in and around the lesion and sprayed over the surface of the ulcer. This decision was supported by previous reports of cases in which collagen-PVP treatment was successfully used (injecting intramuscularly and subcutaneously for patients with rheumatoid arthritis and scleroderma, and application to the surface of dermatological ulcers secondary to venous insufficiency [4][5][6], as well as in the case described in our previous publication [3]). The patient consented to the use of the biological compound for treatment.…”

“…This is possibly accomplished by downregulating proinflamamatory cytokines and adhesion molecules such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1, interleukin-1beta, tumour necrosis factor-alpha and platelet-derived growth factor (3,(7)(8)(9)(10). Intralesional injection of collagen-PVP once a week for one to three months into human hypertrophic scars or scleroderma lesions diminishes pruritus, pain, erythema, volume and inflammatory infiltrates (5,11). This product makes tissue architecture resemble normal skin and modifies the histological and biochemical pattern of fibrosis without changing the total collagen content (12).…”

Polymerized-Type I Collagen Induces a High Quality Cartilage Repair in a Rat Model of Osteoarthritis

“…Local drug delivery strategies may provide for the development of more successful OA treatment outcomes that have potential to reduce local joint inflammation, reduce joint proteolysis, offer pain relief, and restore activities of daily living levels and diarthrodial joint function. For this reason, we have evaluated the effect of a γ-irradiated mixture of a telopeptidic porcine type I collagen and polyvinylpyrrolidone (polymerized-type I collagen), which has anti-inflammatory properties [14,15]. One percent polymerized-type I collagen addition to synovial tissue cultures from non-rheumatoid arthritis (RA) and RA does not induce any change in DNA concentration or metabolism.…”

“…The rationale to inject IA polymerized-type I collagen was based on the encouragement from previous experience related to the biodrug effects (anti-inflammatory and tissue regenerator effects) observed during the course of the treatment of hypertrophic scars, scleroderma (SSc) skin lesions and RA patients [14][15][16][17][18][19][20][21].…”